No abstract

Introduction: CKD represents a progressive irreversible decline in the glomerular filtration rate (GFR). A common phenomenon in renal failure is progressive renal function loss irrespective of the underlying cause of the kidney disease. Hypermagnesaemia is often associated with undetected renal impairment and excessive oral administration of magnesium containing drugs (e.g. laxatives or antacids) or with advanced CKD. The present study was conducted to assess serum magnesium levels in cases with chronic renal failure Material and Methods: It was observational study carried out at Tertiary Institute to assess the levels of serum magnesium in chronic renal failure patients. A total of 80 patients were selected by simple random sampling with chronic renal failure. Results: It was shown that majority of patients were male (58.75%). Majority of patients were having hypertension (60%) followed by diabetes mellitus (43.75%). The serum magnesium among patients showed that majority of patients presented with hypermagnesaemia and serum magnesium level was low in patients with dialysis. Conclusion: Serum magnesium is a worthwhile tool in assessing duration of disease, morbidity and mortality in patients with chronic renal failure.

No abstract

No abstract

Oral glucocorticoids are efficacious for treating respiratory diseases but with a high risk to induce diabetes. We analysed a subset of patients from the Redi iron ore miners from a rural setting (n=25,500), who were newly diagnosed diabetics on extensive chronic methylprednisolone equivalent glucocorticoid dose of ≥4 mg/day for at least 3 months for treatment of respiratory ailments due to occupational hazard (n=1100, males= 660, females=4400). t test and Fisher's exact test were used for the statistical analysis. The mean HbA1c was 7.1% (SD ± 0.62, 95% CI 7-7.3), mean age 51 years (SD ± 14, 95% CI 48 - 54), mean BMI 26 kg/m2 (SD ± 3.6, 95% CI 25 - 27), mean Fasting Plasma Glucose 146 mg/dl (SD ± 49, 95% CI 136-155) mg/dl, mean Post Prandial Glucose 207mg/dl (SD±74, 95% CI 192 - 221). HbA1c at diagnosis in the relatively low risk group (young - normal weight group with age < 40 years, BMI <25 kg/m2) (n=231) was less than the high risk group (older - overweight with age > 40 years, BMI >25 kg/m2) (n=616); mean HbA1c 6.7% (SD±0.33, 95% CI 6.5 - 6.8) vs. mean HbA1c 7.3% (SD±0.65, 95% CI 7.1 - 7.5) (p<0.0001). There was a significant correlation for a high propensity of relatively younger <50 years (n=506) and near normal weight people with BMI < 26 kg/m2 (n=594) to develop GIDM (p=0.006). We observed that high incidence of GIDM (4.31%) is an alarmingly harmful problem which has pronounced comorbid implications, especially in the younger, economically productive population in the limited resource setting. The health care professionals need to be educated to limit the use of glucocorticoids to inhalational therapy with minimal systemic effects. Specific pathophysiological approach to address the steroid induced insulin resistance in this population, makes the treatment of GIDM difficult, which calls for action to limit the mining activities and mitigate the risk of chronic complications due to diabetes. Disclosure V. Redkar: None. S. Redkar: None. M. Inamdar: None. A. Inamdar: None. S. Redkar: None. M. Jagtap: None. S. Rane: None. S.V. Kulkarni: None. J. Deshpande: None. U. Wadhwa: None.